ASCO Annual Meeting to Highlight Clinical Oncology Findings from ...

ASCO Annual Meeting to Highlight Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA)

Presentations and e-publications from SCCA clinicians to feature the latest research on breast, gastrointestinal, genitourinary, lung, renal and sarcoma cancers, and hematological malignancies

Seattle, Wash. (May 21, 2020) ? Seattle Cancer Care Alliance (SCCA), announced today the new findings from its clinicians that will be featured at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program May 29-31, 2020.

SCCA clinicians contributed to discoveries from clinical trials across multiple cancer types, including results from immunotherapy clinical trials. They provided perspectives on the clinical impact of COVID19 on patients with cancer and on financial issues associated with clinical trials and cancer treatment. They also contributed to new findings related to genetic testing, cardiovascular disease among women with breast cancer and personalized cancer care.

"As the only NCI* and NCCN* designated cancer center in the state of Washington, SCCA was established, in part, to help bring promising new treatments to patients faster," said Nancy Davidson, MD, president and executive director of Seattle Cancer Care Alliance and a former ASCO president. "The presentations and publications with which our specialists are associated at ASCO demonstrate SCCA's expertise in cancer diagnosis and treatment, including the clinical impact of COVID-19. They also represent some of the latest findings in clinical research that will enhance patient care today and into the future."

More information about SCCA's presentations and publications at ASCO is available at

Oral Presentations

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis Abstract: LBA1 SCCA author: Petros Grivas, MD, PhD, Clinical Director, Genitourinary Medical Oncology EMBARGO: Thursday, May 28, 5:00 p.m. ET

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) Abstract: LBA110 SCCA author: Petros Grivas, MD, PhD, Clinical Director, Genitourinary Medical Oncology

EMBARGO: Thursday, May 28, 5:00 p.m. ET

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA) Abstract: 4504 SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab in combination with durvalumab for patients with advanced hepatocellular carcinoma Abstract: 4508 SCCA author: William P. Harris, MD

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) Abstract: 5000 SCCA author: Petros Grivas, MD, PhD, Clinical Director, Genitourinary Medical Oncology

FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatmentrefractory advanced renal cell carcinoma (aRCC) Abstract: 5007 SCCA author: Scott Tykodi, MD, PhD

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC) Abstract: 500 SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416) Abstract: 1001 SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded) Abstract: 1002 SCCA Author: Shaveta Vinayak, MD, MS

Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC) Abstract: 5007

SCCA Author: Scott Tykodi, MD

Poster Presentations

Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial Abstract: 4618 SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC-MRD Consortia) Abstract: 4108 SCCA author: Stacey Cohen, MD

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Abstract: TPS4671 SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer Abstract: 4018 SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD Abstract: 7010 SCCA author: Veena Shankaran, MD, MS

A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01) Abstract: 4582 SCCA author: David Zhen, MD

Cost implications of clinical trial (CT) participation in metastatic non-small cell lung cancer (NSCLC) Abstract: 7084 SCCA authors: Keith Eaton, MD, PhD, Service Medical Director, Bernardo Goulart, MD, and Renato Martins, MD, MPH, Clinical Director, Thoracic, Head and Neck Oncology

Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients at the Puget Sound VA Prostate Oncology Clinic Abstract: 1578 SCCA authors: Heather Cheng, MD, PhD, Director, Prostate Cancer Genetics Clinic, and Robert Montgomery, MD

Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427 Abstract: 5024

SCCA author: Scott Tykodi, MD, PhD

Title: Relation between measurable residual disease and morphologic relapse in AML Abstract: 7535 SCCA author: Lauren Shih, MD

A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+ metastatic breast cancer Abstract: TPS1103 SCCA Author: William Gwin, MD

Predictive model of aromatase inhibitor non-adherence using patient-reported outcomes in women with breast cancer (SWOG S1105) Abstract: 12019 SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

Risk of cardiovascular disease in women with and without a history of breast cancer: The Pathways Heart Study Abstract: 12016 SCCA Author: Heather Greenlee, ND, PhD, Director, Integrative Medicine Program

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB) Abstract: 1043 SCCA Author: Jennifer Specht, MD

A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer Abstract: TPS 1104 SCCA Author: Jennifer Specht, MD

Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care on the ground Abstract: 2011 SCCA Author: Benjamin Anderson, MD

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Abstract: 4671 SCCA Author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A Abstract: 5069 SCCA Author: Scott Tykodi, MD

Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) Abstract: 1070 SCCA Author: Hannah Linden, MD

Gender differences in faculty rank and subspecialty choice in academic medical oncology Abstract: 11013 SCCA Author: Nancy Davidson, MD, President and Executive Director

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma Abstract: 11517 SCCA Author: Michael Wagner, MD

PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)--A PrECOG LLC study. Abstract: 9003 SCCA Author: Bernardo Goulart, MD

ePublications

Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss Abstract: e16050 SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Treatment patterns in pancreatic cancer: Differences between expert and community practitioners Abstract: e19207 SCCA author: E. Gabriela Chiorean, MD, Clinical Director, Gastrointestinal Medical Oncology

Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers Abstract: e16771 SCCA author: Andrew Coveler, MD, Director, Pancreatic Cancer Specialty Clinic

ER, PR, and HER2 expression in Ugandan breast cancer patients: An evaluation of in-country RT-PCR compared to IHC Abstract: E19009 SCCA Author: Julie Gralow, MD, Clinical Director, Breast Medical Oncology

Publication Only

Patient-centered pathology reports for breast cancer care: Interim results of a randomized pilot study Abstract: e19157 SCCA Author: Sara Javid, MD, Director, Breast Health Clinic

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download